source
- Genentech pays $45M upfront to DualityBio for ADC platform targeting resistant cancersGenentech has agreed to pay DualityBio $45 million upfront for rights to its antibody‑drug conjugate (ADC) technology, with the agreement offering more than $1 billion in potential milestone paymen…
- BioNTech-Genentech halts colorectal cancer vaccine trial after higher death rate in vaccine armBioNTech and Genentech stopped a phase 2 trial of their personalized mRNA vaccine BNT122 in patients with stage 2 or 3 colorectal cancer after an independent data safety monitoring board found more…